AbbVie Secures Legal Victory, Delaying Generic Competition for Rinvoq Until 2037

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-09-11 16:48:02

BTCCSquare news:

AbbVie shares surged 4.2% after settling litigation with generic drugmakers, effectively blocking competition for its autoimmune drug Rinvoq until at least April 2037. The resolution removes a key overhang on one of AbbVie's fastest-growing assets, which generated $3.75 billion in the first half of 2025.

Rinvoq's strong performance in treating ulcerative colitis and Crohn's disease positions it as a cornerstone of AbbVie's post-Humira growth strategy. While playing second fiddle to Skyrizi in the autoimmune portfolio, the extended market exclusivity provides clear visibility for revenue streams through the next decade.

By:

Log in to Reply

Regulatory Shifts Propel Crypto from Margins to Mainstream

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.